We have updated our rollout forecasts for Tuzistra® XR and the four follow-on cough-cold programmes, resulting in significant reductions to expected prescription volumes for FY2018-20. We reiterate our Hold recommendation with a revised target price of 14p (from 28p).
24 Nov 2017
N+1 Singer - Vernalis - Reduction in cough cold forecasts
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Vernalis - Reduction in cough cold forecasts
We have updated our rollout forecasts for Tuzistra® XR and the four follow-on cough-cold programmes, resulting in significant reductions to expected prescription volumes for FY2018-20. We reiterate our Hold recommendation with a revised target price of 14p (from 28p).